StoryTest
Kyverna reports one-year data for miv-cel in stiff person syndrome and myasthenia gravis
Kyverna TherapeuticsKYV-101 (miv-cel)
Kyverna presented longer-term follow-up data at one year showing durable clinical benefit in both stiff person syndrome and generalized myasthenia gravis cohorts from the Phase 2 registrational trials. KYSA-8 in SPS demonstrated sustained clinically meaningful responses with excellent durability and safety profile. KYSA-6 in gMG progressing with enrollment advancing in Phase 3.